[A26-31] Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 15.06.2026
Project no.:
A26-31
Commission:
Commission awarded on 16.03.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with metastatic hormone-sensitive prostate cancer (mHSPC) and breast cancer-associated gene (BRCA)1/2 mutations (germline and/or somatic)
- Patients with newly diagnosed high-risk mHSPC and BRCA1/2 mutations (germline and/or somatic): added benefit not proven
- Patients not newly diagnosed and who do not have high-risk mHSPC with BRCA1/2 mutations (germline and/or somatic): added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-31
| Project no. | Title | Status |
|---|---|---|
| A23-107 | Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |